A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease

Clinical Nephrology

Volumn 65, Issue 6, 2006, Pages 415-418

  Tarrass, F ^a,b   Yazidi, A ^a   Sif, H ^a   Zamd, M ^a   Benghanem, M G ^a   Ramdani, B ^a  

^a IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^b NONE   (Morocco)

Author keywords

Alfacalcidol; End stage renal disease; Hemodialysis; Secondary hyper parathyroidism

Indexed keywords

ALBUMIN; ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCIUM; CALCIUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS; UN ALFA;

ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MALE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 33744965108     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP65415     Document Type: Article

References (12)

1. 3 in patients on chronic hemodialysis. Am J Nephrol. 1992; 12. 311-318.
2. 3 treatment of secondary hyperparathyroidism in uraemia. J Intern Med. 1996; 239: 353-360.
3. Delmez JA, Tindira C, Grooms P et al. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: A role for increased sensitivity to calcium. J Clin Invest. 1989; 83: 1349-1355.
4. Herrmann P, Ritz E, Schmidt-Gayk H et al. Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron. 1994; 67: 48-53.
5. Hsu C, Patel S, Young E, Vanholder R. The biological action of calcitriol in renal failure. Kidney Int. 1994; 46: 605-612.
6. Klaus G, Mehls O, Hinder E, Ritz E. Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? Lancet. 1991; 337: 800-801.
7. Kremer R, Bolivar I, Goltzman D, Hendy G. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology. 1989; 125: 935-941.
8. Lee WT, Padayachi K, Collins JF, Cundy T.A. comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism. J Am Soc Nephrol. 1994; 5: 1344-1348.
9. Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int Suppl. 2002; 80: 155-160.
10. Sherrard DJ, Hercz G, Pei Y, Maloney NA et al. The spectrum of bone disease in end-stage renal failure: An evolving disorder. Kidney Int. 1993; 43: 436-442.
11. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int. 1989; 35: 1049-1056.
12. 3 on secondary hyperparathyroidism in patients on maintenance hemodialysis. Nippon Jinzo Gakkai Shi. 1990; 32: 1117-1123.